他汀类药物通常用于降低胆固醇，并已被证明对动脉粥样硬化性心血管疾病具有显着益处。然而，他汀类药物治疗是否会降低癌症风险仍存在争议。在这项研究中，我们通过对随机对照试验进行全面的荟萃分析，研究了他汀类药物治疗对癌症发病率和死亡率的影响。通过 Cochrane、Embase、Medline 和 PubMed 进行系统检索，以查找符合条件的随机对照试验相关数据他汀类药物治疗和肿瘤学。我们的主要终点是癌症发病率和死亡率。本研究使用了固定效应模型。该荟萃分析包括三十五项随机对照研究。 28 项纳入的研究报告了癌症发病率，18 项研究报告了癌症死亡率。汇总结果表明，与安慰剂相比，他汀类药物并未降低癌症发病率[OR = 0.99，95% CI (0.95，1.03)]。此外，他汀类药物并未降低癌症死亡率[OR = 0.99，95% CI (0.91，1.07)]。这项研究还进行了一些亚组分析，结果显示他汀类药物对泌尿生殖癌和乳腺癌等癌症亚型没有影响。他汀类药物的类型以及他汀类药物的长期治疗均对癌症发病率和死亡率没有影响。通过综合分析，我们发现他汀类药物治疗在保护心血管系统的同时并不能降低癌症发病率或死亡率。Prospero CRD42022377871.© 2023。作者。

Statins are routinely prescribed to lower cholesterol and have been demonstrated to have significant benefits in atherosclerotic cardiovascular disease. However, whether statin therapy has effects on cancer risk remains controversial. In this study, we investigated the influence of statin therapy on cancer incidence and mortality by conducting a comprehensive meta-analysis of randomized controlled trials.Systematic searches by Cochrane, Embase, Medline, and PubMed were performed to locate data from eligible randomized controlled trials related to statin therapy and oncology. Our main endpoints were cancer incidence and mortality. Fixed-effects models were used in this study.This meta-analysis comprised thirty-five randomized controlled studies. Twenty-eight included studies reported cancer incidence, and eighteen reported cancer mortality. The pooled results indicated no reduction in cancer incidence with statins compared to placebo [OR = 0.99, 95% CI (0.95, 1.03)]. In addition, statins did not decrease cancer mortality [OR = 0.99, 95% CI (0.91, 1.07)]. This study also performed a number of subgroup analyses, which showed no effect of statins on cancer subtypes such as genitourinary and breast cancer. Neither the type of statin nor long-term treatment with statins had an effect on cancer incidence and mortality.Through comprehensive analysis, we found that statin therapy does not reduce cancer incidence or mortality while protecting the cardiovascular system.Prospero CRD42022377871.© 2023. The Author(s).